Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jun 1, 2012
Suzanne Topalian, MD, Professor of Surgery and Oncology at the Johns Hopkins University School of Medicine, discusses early-stage results of the targeted immune agent BMS-936558, a co-inhibitor of the programmed death-1 (PD-1) receptor that is expressed by activated T cells.